PRASUGIL A 75: Dual Antiplatelet Therapy for Cardiovascular Protection

PRASUGIL A 75: Dual Antiplatelet Therapy for Cardiovascular Protection

PRASUGIL A 75 is a combination medication containing Prasugrel HCL (75mg) and Aspirin, designed to provide dual antiplatelet therapy for individuals at risk of cardiovascular events. This combination is known for its efficacy in inhibiting platelet aggregation and reducing the risk of blood clots.

Key Benefits:

1. Dual Antiplatelet Therapy: PRASUGIL A 75 combines the antiplatelet effects of Prasugrel HCL and Aspirin, offering a synergistic approach to preventing blood clots and cardiovascular events.
2. Platelet Inhibition: The medication inhibits platelet aggregation, reducing the formation of blood clots that can lead to heart attacks or strokes.
3. Reduced Cardiovascular Risk: PRASUGIL A 75 helps reduce the risk of cardiovascular events, including myocardial infarction (heart attack), stroke, and stent thrombosis, in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI).
4. Once-Daily Dosage: With a convenient once-daily dosing regimen, PRASUGIL A 75 ensures ease of use and improved patient compliance.

How It Works:

• Prasugrel HCL (75mg): Prasugrel is a platelet aggregation inhibitor that blocks the P2Y12 adenosine diphosphate (ADP) receptor on platelets, preventing platelet activation and aggregation.

• Aspirin: Aspirin is an antiplatelet agent that inhibits the production of thromboxane A2, further reducing platelet aggregation and clot formation.

Usage and Dosage:

• Follow your healthcare provider's instructions regarding the dosage and usage of PRASUGIL A 75.
• The typical dosage is one tablet once daily, taken orally with or without food.
• Use caution and consult your doctor if you have a history of bleeding disorders or are taking other medications that increase the risk of bleeding.

Precautions:

• Inform your doctor about any existing medical conditions, allergies, or medications you are taking before starting PRASUGIL A 75.
• Monitor for signs of bleeding, such as easy bruising, prolonged bleeding from cuts, or unusual bleeding, while taking this medication.
• Avoid sudden discontinuation of PRASUGIL A 75 without medical advice, as it may increase the risk of blood clotting.

Conclusion:

PRASUGIL A 75 is a reliable combination medication for dual antiplatelet therapy, offering effective platelet inhibition and reducing the risk of cardiovascular events in high-risk patients. With its once-daily dosing, proven efficacy, and cardiovascular protection, it plays a crucial role in promoting cardiovascular health and well-being.A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics,General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.For further information: EMAIL:  info@sterispharma.com  / contact@sterispharma.com   CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 BUY NOW